Clinical Trials Logo

Filter by:
NCT ID: NCT02585934 Completed - Alzheimer's Disease Clinical Trials

Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

Start date: October 2015
Phase: Phase 3
Study type: Interventional

This study seeks to confirm a demonstrated treatment effect of intepirdine (RVT-101) as an adjunctive therapy to donepezil for the treatment of subjects with Alzheimer's disease.

NCT ID: NCT02585258 Completed - Clinical trials for RheumatoId Arthritis

The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study

Gloria
Start date: June 30, 2016
Phase: Phase 4
Study type: Interventional

Comparing the cost-effectiveness and safety of additional low-dose glucocorticoid in treatment strategies for elderly patients with rheumatoid arthritis: The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study (GLORIA)

NCT ID: NCT02584855 Completed - Psoriatic Arthritis Clinical Trials

A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

SPIRIT P3
Start date: September 14, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.

NCT ID: NCT02581995 Completed - Macular Edema Clinical Trials

Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.

AQUA
Start date: November 19, 2015
Phase: Phase 4
Study type: Interventional

To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.

NCT ID: NCT02581345 Completed - Psoriasis Clinical Trials

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Start date: September 2015
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.

NCT ID: NCT02579252 Completed - Alzheimer's Disease Clinical Trials

24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease

ADAMANT
Start date: March 2016
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with mild Alzheimer's disease. 60% of participants will receive AADvac1 and 40% of participants will receive placebo.

NCT ID: NCT02576717 Completed - Multiple Sclerosis Clinical Trials

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Start date: October 16, 2015
Phase: Phase 3
Study type: Interventional

The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.

NCT ID: NCT02576574 Completed - Clinical trials for First Line Non-Small Cell Lung Cancer

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Start date: October 29, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors.

NCT ID: NCT02575833 Completed - Stable Angina Clinical Trials

Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)

Start date: November 23, 2015
Phase: Phase 2
Study type: Interventional

A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.

NCT ID: NCT02571777 Completed - Asthma Clinical Trials

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

Start date: December 8, 2015
Phase: Phase 3
Study type: Interventional

The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320) μg via Concept1 in poorly controlled asthmatics as determined by pulmonary function testing and effects on asthma control.